Ministry of Health (Minsa) officials reported through a press release published in official media that they had administered a total of 92,410 doses in seven days of the “first vaccination campaign against human papillomavirus (HPV).” Girls aged between 10 to 14 years.
He elaborated that so far they have made 36 percent progress on the target of 259,907 girls between the ages of 10 and 14 whom they want to vaccinate.
According to reports from health officials, the vaccination day against human papillomavirus started on November 6 and will continue till January 15, 2024.
Read: MINSA will administer vaccine against human papillomavirus from November 6
The HPV vaccine is administered “in all health units” in the country, through door-to-door visits to regions, communities and neighborhoods throughout the national territory, at health fairs, and in public and private schools, according to MINSA on its website.
According to MINSA, when administering the HPV immunizer, guardians of minors must sign “consent or authorization” and present the minor’s vaccination card or identity document, which allows to verify their age.
HPV vaccine is 98% effective
“The level of protection of the vaccine against HPV and cervical infection is very high, with effectiveness around 98%,” MINSA reported in a publication on its website.
You may be interested in: MINSA delays application of HPV vaccine in Nicaragua
He highlighted that vaccinators, for those who have already had sexual intercourse and possibly already been exposed to human papillomavirus, “reduce the effectiveness and safety of these types of vaccines. ” In this context, he said, they “decided to give priority to girls between 10 and 14 years old, because they have not started a sexual life and therefore have no risk, so the effectiveness in preventing cancer is higher. ”
“By vaccinating girls, we intend to cut the chain of transmission of this virus,” he said.
Health officials also clarified that vaccination against HPV is safe, because “the complications that this vaccine can cause in people are rare, those that do occur are similar to those that any other vaccine might introduce, such as “Slight pain at the site of application.”